FDA OKs first over-the-counter oral birth control tablet


The U.S. Food and Drug Administration on Thursday announced it had approved norgestrel tablets for over-the-counter sales, making the medication the first instance of a non-prescription oral birth control pill to be okayed by the government in the nation's history. "Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online," the FDA said in a press release.
The medicine, known as "Opill," is expected to be available in early 2024, its Dublin-based manufacturer, Perrigo Company, told the New York Times. While no price for the medication has been announced, Frederique Welgryn, the company's Global Vice President for Women's Health, said in a statement accompanying the FDA's announcement that Perrigo is committed to making Opill "accessible and affordable to women and people of all ages."
Norgestrel was initially approved for prescription use by the FDA 50 years ago, with Perrigo Company launching its push to make the medication available without a prescription in 2015, according to an administration memo authored by Dr. Karen Murry, Deputy Director of the FDA's Office of Nonprescription Drugs.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"Increasingly, women in some parts of the U.S. have few options once an unintended pregnancy occurs," Murry noted, in direct reference to the ongoing push by conservative legislators and activists to limit reproductive health options for women seeking to end their pregnancies. "Thus, giving women greater ability to prevent a pregnancy, rather than to face wrenching personal choices after an unintended pregnancy occurs, has the potential for individual and societal benefit."
Opill's approval comes just months after an independent panel of 17 agency advisors voted unanimously that the medication's over-the-counter benefits outweighed any potential risks, including to those users who have had breast cancer, or are on other hormone-based contraceptives at the time.
According to the FDA, "almost half of the 6.1 million pregnancies in the U.S. each year are unintended," which has been linked to "negative maternal and perinatal outcomes." A 2016 study published in the Journal of Women's Health found that nearly one-third of all women who have tried to get a prescription or refill of their hormonal contraceptives had encountered difficulties doing so.
Use of Opill according to its directions is not only safe, explained Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, but it is also "expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Rafi Schwartz has worked as a politics writer at The Week since 2022, where he covers elections, Congress and the White House. He was previously a contributing writer with Mic focusing largely on politics, a senior writer with Splinter News, a staff writer for Fusion's news lab, and the managing editor of Heeb Magazine, a Jewish life and culture publication. Rafi's work has appeared in Rolling Stone, GOOD and The Forward, among others.
-
Israeli air strikes in Gaza: why has ceasefire collapsed?
Today's Big Question Start of 'broader and more sustained military operation' denounced by domestic groups representing hostage families
By The Week UK Published
-
OpenAI's new model is 'really good' at creative writing
Under the Radar CEO Sam Altman says he is impressed. But is this merely an attempt to sell more subscriptions?
By Theara Coleman, The Week US Published
-
Crossword: March 18, 2025
The Week's daily crossword
By The Week Staff Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published